The investigational new drug application for Zabalafin Hydrogel for the treatment of mild to moderate atopic dermatitis has ...
The FDA cleared the investigational new drug application for LTZ-301, a first-in-class myeloid engager immunotherapy, with a ...
BioRestorative Therapies, Inc. ("BioRestorative”, "BRTX” or the "Company”) (NASDAQ:BRTX), a clinical stage regenerative ...
Vantage Specialty Chemicals, Inc., (Vantage) today announced that its VYCERIN™ API Glycerin, USP is listed on the Drug Master File (DMF-040171) with the U.S. Food and Drug Administration ...
ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025Oral small ...
The Food and Drug Administration granted fast track designation to AUTX-703 for relapsed or refractory acute myelogenous ...
Allogene Therapeutics is undervalued. Read more on ALLO stock's cash runway, innovative CAR-T therapies, and market expansion ...
BRTX-100 is the first and only stem cell product candidate cleared to be evaluated in the cervical degenerative disc disease setting - - IND clearance expands Company's advanced clinical pipeline for ...
The FDA has granted AUTX-703, a first-in-class oral KAT2A/B degrader, fast track designation for the treatment of ...
Percheron Therapeutics Ltd has submitted a non-binding proposal to an international pharmaceutical company to in-license a new drug development program focused on a rare neurological disease.